Salford Royal NHS Foundation Trust

Running trials

• Recruiting

  Study of WAL0921 in Patients With Glomerular Kidney Diseases

  NCT06466135· Phase 2· Source

• Recruiting

  A Global Prospective Observational Registry of Patients With Pompe Disease

  NCT06121011· Source

• Enrolling by invitation

  An Open-label Study of XEN1101 in Epilepsy

  NCT05718817· Phase 3· Source

• Recruiting

  A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures

  NCT05667142· Phase 3· Source

• Active, not recruiting

  Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)

  NCT05248646· Phase 3· Source

• Active, not recruiting

  Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)

  NCT04586023· Phase 3· Source

• Recruiting

  Pragmatic Randomised Trial of High Or Standard PHosphAte Targets in End-stage Kidney Disease (PHOSPHATE)

  NCT03573089· Source

• Active, not recruiting

  Arrhythmia Burden, Risk of Sudden Cardiac Death and Stroke in Patients With Fabry Disease

  NCT03305250· Source

• Active, not recruiting

  IVIG and Rituximab in Antibody-associated Psychosis - SINAPPS2

  NCT03194815· Phase 2· Source

• Active, not recruiting

  The British Heart Foundation SENIOR-RITA Trial

  NCT03052036· Source

• Recruiting

  Gaucherite - A Study to Stratify Gaucher Disease

  NCT03240653· Source

• Active, not recruiting

  Investigating Genes in Patients With Polymyositis and Dermatomyositis

  NCT01171573· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Epilepsy2 recruiting
• Chronic kidney disease1 recruiting
• Gaucher disease1 recruiting
• IgA nephropathy1 recruiting
• Pompe disease1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80

  NCT05348785· Phase 2· Source

• Completed

  AURORAX-0087A: GAG Scores for Surveillance of Recurrence in Leibovich Points ≥5 Non-metastatic ccRCC

  NCT04006405· Source

• Completed

  CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson's Disease)

  NCT04226248· Phase 3· Source

• Completed

  A Study to Assess the Long-term Safety and Efficacy of ATB200/AT2221 in Adult Subjects With Late-Onset Pompe Disease (LOPD)

  NCT04138277· Phase 3· Source

• Completed

  Ustekinumab Real World Evidence Study

  NCT07748338· Source

• Completed

  Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis

  NCT04036435· Phase 3· Source

• Completed

  Rostock International Parkinson's Disease Study (ROPAD)

  NCT03866603· Source

• Completed

  WORKWELL: Testing Work Advice for People With Arthritis

  NCT03942783· Source

• Completed

  This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS)

  NCT03599245· Phase 3· Source

• Completed

  Long-term Extension to Study AC-058B301 to Investigate Safety, Tolerability and Disease Control of Ponesimod 20 mg in Patients With Relapsing Multiple Sclerosis

  NCT03232073· Phase 3· Source

• Completed

  First-In-Human Study to Evaluate Safety, Tolerability, and PK of Intravenous ATB200 Alone and When Co-Administered With Oral AT2221

  NCT02675465· Phase 1/2· Source

Trial sites

• Salford Royal NHS Foundation Trust4 trials
• Salford Royal NHS Foundation Trust16 trials
• Salford Royal NHS Foundation Trust - Greater Manchester Neuroscience Centre (GMNC)2 trials
• Salford Royal NHS Foundation Trust - Site #5831 trial

Conditions

Diseases this institution publishes on or runs trials for.

• Pompe disease11 works · 3 trials